Day: August 6, 2024

VANCOUVER, British Columbia, Aug. 06, 2024 (GLOBE NEWSWIRE) — Finning International Inc. (TSX: FTT) (“Finning”, the “Company”, “we”, “our” or “us”) reported second quarter 2024 results today. All monetary amounts are in Canadian dollars unless otherwise stated. HIGHLIGHTSAll comparisons are to Q2 2023 results unless indicated otherwise.Q2 2024 EPS (1) was $1.02, up 2% from Q2 2023 and a record for Q2. Q2 2024 free cash flow (3) of $330 million was a Q2 record, compared to $31 million in Q2 2023. Net debt to Adjusted EBITDA (1)(2)(4) was 1.8 times at June 30, 2024, compared to 1.7 times at December 31, 2023. Q2 2024 revenue of $2.9 billion and net revenue (2) of $2.6 billion were up 5% and 3%, respectively. Product support revenue was up 0.4% from Q2 2023 and 8% higher compared to Q1 2024. SG&A (1) as a percentage of net...

Total revenue from continuing operations increased 8%; constant currency organic revenue grew 6% As reported EPS from continuing operations increased to $1.41; adjusted EPS increased to $2.03 Fiscal 2025 outlook reiteratedDUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%. “We are pleased with the start to our new fiscal year and continue to experience positive momentum across each of our segments,” said Dan Carestio, President...

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024. “Having expanded and extended our ASPIRE study to 50 patients and 36 weeks, respectively, to better assess the efficacy and durability of UBX1325 compared to aflibercept, we have been laser-focused on enrollment and execution this quarter,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “I’m pleased to report that due to the excellent performance of our clinical operations team and the enthusiasm and engagement of our investigators, we have not just met, but have exceeded our enrollment goal in this study.” UBX1325 (foselutoclax) is...

ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALL ODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatment Cash position of $273 million as of June 30, 20241; cash runway projection into 2026NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. “Over the past months, we have achieved a significant milestone with the granting of ODD designations by the Food and Drug Administration and the European Commission, complemented by the FDA’S Rare Pediatric Disease...

Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance range Second Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) million Updates FY 2024 guidanceGAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2024. “In the first half of the year, we made great progress to stabilize our financial position by strategically divesting assets, resolving several legacy issues, and securing operational cash flow and working capital improvements,” said Joe Papa, president and CEO at Emergent. “As a result, we expect to exceed $200 million in debt reduction by the end of the year. With a sharpened focus on our core products, operationalizing a leaner, more flexible footprint with...

Sales of $544 million Net income (including discontinued operations) of $6 million, or $0.12 per diluted share Income from continuing operations of $31 million, or $0.60 per diluted share Adjusted income from continuing operations excluding intangibles amortization expense of $75 million, or $1.49 per diluted share Adjusted EBITDA of $139 million, up five percent from the prior-year quarter Cash flows provided by operating activities of $128 million; ongoing free cash flow2 of $112 million Repurchased 1.3 million shares; $770 million remaining under existing authorizationWILMINGTON, Del., Aug. 06, 2024 (GLOBE NEWSWIRE) — Ashland Inc. (NYSE: ASH) today announced financial results1 for the third quarter of fiscal year 2024, which ended June 30, 2024, and issued its outlook for fourth quarter and full-year fiscal 2024. The global...

TORONTO, Aug. 06, 2024 (GLOBE NEWSWIRE) — Martinrea International Inc. (TSX : MRE), a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems, today announced the release of its financial results for the second quarter ended June 30, 2024, and declared a quarterly cash dividend of $0.05 per share. SECOND-QUARTER HIGHLIGHTSTotal sales of $1,301.8 million, production sales of $1,263.7 million. Diluted net earnings per share of $0.54 and Adjusted Net Earnings per Share(1) of $0.58. Adjusted Operating Income Margin(1) of 6.3%. Adjusted EBITDA(1) of $166.1 million, a new quarterly record for the Company. Free Cash Flow(1) (excluding principal payments of IFRS-16 lease liabilities) was $51.7 million, a notable improvement...